ClinicalTrials.gg
CompletedNCT05954988Updated Jul 31, 2025Results posted

A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients

A Phase 1 interventional study of LTI-03 and Placebo in Idiopathic Pulmonary Fibrosis, sponsored by Rein Therapeutics. Completed at 7 sites in 3 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2025-07-31.

Sponsored by Rein Therapeutics · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States — 37 open to participants now, 51 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · United States.

Enrollment
144th of 188
24 · median 61
Started
2023
with 13 others
Phase 1
39 of 236
3 open now
Registered
178th of 236
by date

Among the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, this one is the 144th largest by enrollment of the 188 interventional ones that give a count, is one of 14 that started in 2023, is one of 39 in phase 1, and was the 178th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

37 of the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States are open now. Recruiting first, the newest first:

32 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, or all of them as a file.
02

Study summary

This study will assess the safety and tolerability of inhaled LTI-03 in treatment naïve participants with newly diagnosed IPF.

Read the detailed description

This is a randomized, double-blind, placebo controlled, multi-center, dose escalation, safety and tolerability study of LTI-03 or placebo administered by inhalation in participants recently diagnosed with idiopathic pulmonary fibrosis that have not received prior treatment with anti-fibrotic agents.

The study will contain 2 dose cohorts which will run sequentially.

Eligible participants will be randomized in a 3:1 ratio to either LTI-03 or placebo. Safety data will be reviewed on an ongoing basis. Enrollment in the second cohort will not begin until the Cohort 1 safety data has been reviewed.

The Treatment Period will be 14 days, with subjects self-administering study drug using a provided commercially available dry-powder inhaler.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis

Keywords

  • IPF
  • idiopathic pulmonary fibrosis
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female subject of age 40 years or older.
  2. Willing and able to provide written .
  3. Diagnosis of IPF within 3 years of Screening as confirmed by HRCT of chest or lung as defined by ATS/ERS/JRS/ALAT guideline.
  4. Forced vital capacity (FVC) percent predicted ≥ 40%.
  5. Diffusion capacity of the lungs for carbon monoxide (DLCO) percent predicted ≥ 30 and ≤ 80.
  6. Forced expiratory volume 1 ()/FVC ≥ 0.7.

Exclusion criteria

Exclusion Criteria:

  1. Interstitial lung disease other than IPF.
  2. Evidence of significant obstructive lung disease.
  3. Current diagnosis of asthma.
  4. Treatment with an approved or antifibrotic therapy for IPF within 2 months of the Baseline bronchoscopy.
  5. Use of N-acetyl cysteine or other supplements within 7 days prior to dosing and throughout the Treatment Period.
  6. Inability to use study inhaler device appropriately.
  7. Pulmonary exacerbation within 6 months prior to Screening.
  8. Febrile illness within 7 days prior to dosing.
  9. Participation in a clinical study or treatment with an investigational drug or device within 30 days of the Screening Visit (or 5 half-lives of the investigational agent, whichever is longer).
  10. History or evidence at screening of significant renal impairment with \< 30 mL/min (region specific).
  11. History or evidence at screening of significant hepatic impairment with > 3 mg/dL (> 51.3 µmol/L) and albumin \< 2.8 g/dL (\<28 g/L) and PT prolongation > 6 sec or > 2.3 (region specific).
  12. Serious or active medical or psychiatric condition which, in the opinion of the Investigator, may interfere with treatment, assessment, or compliance with the protocol.
  13. Vaccination within 2 weeks of start of dosing (Day 1) and throughout the Treatment Period.
  14. Subject has severe progressive or uncontrolled, disease that in the judgment of the investigator or designee renders the subject unsuitable for the study.
  15. Positive urine pregnancy test in female subjects of as defined below.
  16. Female subjects who are lactating.
  17. Females of childbearing potential (FOCBP) and men with partners of childbearing potential who do not agree to use an acceptable form of for the duration of study treatment and for at least 90 days after the last dose of study drug. Male subjects who do not agree to refrain from donating sperm during this same period.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    2.5 mg LTI-03 BID

    2.5 mg LTI-03 BID x 14 days

    Drug: LTI-03

  • Experimental
    5 mg LTI-03 BID

    5 mg LTI-03 BID x 14 days

    Drug: LTI-03

  • Placebo comparator
    Placebo

    Matching placebo BID x 14 days

    Drug: Placebo

Interventions

  • DrugLTI-03

    Caveolin-1-Scaffolding-Protein-Derived Peptide

    Also known as: Micronized dry powder in hard 2 piece hypromellose capsules

  • DrugPlacebo

    Matching placebo

    Also known as: Micronized lactose powder in capsule

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-emergent Adverse Events (TEAEs)

    Incidence of TEAEs by dose

    Time frame: 21 days (dosing x 14 days; follow up x 7 days)

07

Results

Posted Jul 31, 2025

Participant flow

Participant flow — Overall Study
Milestone2.5 mg LTI-03 BID5 mg LTI-03 BIDPlacebo
Started996
Completed996
Not completed000

Outcome measures

PrimaryIncidence of Treatment-emergent Adverse Events (TEAEs)

Incidence of TEAEs by dose

Time frame:
21 days (dosing x 14 days; follow up x 7 days)
Reported as:
Number · percentage of participants
Incidence of Treatment-emergent Adverse Events (TEAEs)
percentage of participants2.5 mg LTI-03 BID5 mg LTI-03 BIDPlacebo
Any TEAE66.777.850.0
Any TEAE with CTCAE severity Grade 3 or higher000
Any study drug-related TEAE22.255.616.7
Any TEAE leading to treatment discontinuation000
Any serious TEAE011.10
Any TEAE leading to death000

Adverse events

Collected over From ICF (if serious or related to protocol assessment) or Dosing Day 1 through End of Study Day 21. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
2.5 mg LTI-03 BID0/9 (0%)0/9 (0%)6/9 (66.7%)
5 mg LTI-03 BID0/9 (0%)1/9 (11.1%)7/9 (77.8%)
Placebo0/6 (0%)0/6 (0%)3/6 (50%)
Most frequent serious events
Most frequent serious events
Event2.5 mg LTI-03 BID5 mg LTI-03 BIDPlacebo
Post-procedural feverInjury, poisoning and procedural complications0/91/90/6
Most frequent other events
Showing 10 of 20
Most frequent other events
Event2.5 mg LTI-03 BID5 mg LTI-03 BIDPlacebo
CoughRespiratory, thoracic and mediastinal disorders3/95/92/6
DizzinessNervous system disorders0/90/91/6
Esophageal spasmGastrointestinal disorders0/90/91/6
PalpitationsCardiac disorders0/91/90/6
DysgeusiaNervous system disorders1/90/90/6
Ophthalmic migraineNervous system disorders1/90/90/6
Chest discomfortGeneral disorders1/90/90/6
FatigueGeneral disorders1/90/90/6
VertigoEar and labyrinth disorders0/91/90/6
Dry mouthGastrointestinal disorders0/91/90/6

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)2.5 mg LTI-03 BID5 mg LTI-03 BIDPlaceboTotal
<=18 years0000
Between 18 and 65 years4318
>=65 years56516
Age, Continuous
Age, Continuous(years)2.5 mg LTI-03 BID5 mg LTI-03 BIDPlaceboTotal
Mean67.8 ± 9.7668.4 ± 10.7971.7 ± 6.1569.0 ± 9.19
Sex: Female, Male
Sex: Female, Male(Participants)2.5 mg LTI-03 BID5 mg LTI-03 BIDPlaceboTotal
Female2204
Male77620
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)2.5 mg LTI-03 BID5 mg LTI-03 BIDPlaceboTotal
Hispanic or Latino0000
Not Hispanic or Latino99624
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)2.5 mg LTI-03 BID5 mg LTI-03 BIDPlaceboTotal
American Indian or Alaska Native0000
Asian0000
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White99624
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)2.5 mg LTI-03 BID5 mg LTI-03 BIDPlaceboTotal
United States2103
United Kingdom3238
Germany34210
Australia1213
Height
Height(cm)2.5 mg LTI-03 BID5 mg LTI-03 BIDPlaceboTotal
Mean170.93 ± 9.270169.56 ± 9.530177.17 ± 7.111171.98 ± 9.067
Weight
Weight(kg)2.5 mg LTI-03 BID5 mg LTI-03 BIDPlaceboTotal
Mean84.49 ± 11.70985.36 ± 25.10891.45 ± 11.52986.55 ± 17.446

8 further baseline measures are reported on the registry.

08

Study locations

7 sites
  • University of Alabama
    Birmingham, Alabama 35294, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • Cedars Sinai Medical Center
    Los Angeles, California 90048, United States
  • Agaplesion Evangelisches Krankenhaus Mittelhessen
    Giessen, Germany
  • University of Edinburgh
    Edinburgh, United Kingdom
  • Royal Brompton Hospital
    London, SW3 6HP, United Kingdom
  • Royal Victoria Infirmary
    Newcastle, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2023 to primary completion in Sep 2024, 14 months.

Results were first posted in Jul 2025, 10 months after primary completion.

Of 60 industry-sponsored phase 1 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 14 months is above that.

Counting every sponsor, half of 75 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2022
First posted
Jul 20, 2023
StartActual
Jul 6, 2023
Primary completionActual
Sep 25, 2024
CompletionActual
Sep 25, 2024
Results first posted
Jul 31, 2025
Last update
Jul 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05954988
Lead sponsor
Rein Therapeutics
Responsible party
Sponsor
First posted
Jul 20, 2023
Start date
Jul 6, 2023
Primary completion
Sep 25, 2024
Completion
Sep 25, 2024
Results posted
Jul 31, 2025
Last update
Jul 31, 2025

Study contacts

Steven A. Shoemkaer, MD
study director · Lung Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LTI-03

Start the discussion